For the second year in a row, our Managing Director Cesar Carnicer was interviewed by Joseph Harvey (Animal Pharm), business analyst for IHS Markit.
For sure, in these times of pandemic, we all need to read, hear and talk about things that are going well and bring a little positivity to our daily lives. Although we are rather discreet on the subject, for once we are going to talk about Syva from a more ‘business’ angle.
As this economic analyst’s evocatively titled article points out: ‘Syva’s investment in burgeoning vaccine business undeterred by pandemic’, Syva has remained solid despite the sanitary threat and has been well advised to continue developing its vaccine production activities, which now account for a third of its turnover and which reached a decisive turning point in 2019 with the launch of its multi-strain vaccine against blue tongue disease.
If we had to give some achievements of Syva’s activity in 2020, it is
- A growing turnover;
- A storage capacity that has almost doubled;
- A storage capacity linked to the cold chain dedicated to vaccines that has tripled;
- The establishment of a new subsidiary in Turkey which opens up new horizons;
- The perspective of launching new vaccines that will strengthen its own product portfolio with high focus on quality.
These are all reasons and opportunities to renew its commitment to its customers by keeping its focus on its mission to offer ‘meaningful solutions for animal health’.
More details in the interview with César Carnicer, CEO of Syva, by Joseph Harvey (Animal Pharm) for IHS Markit: Syvas_investment_in_burgeoning_vaccine_business_undeterred_by_pandemic-2
For more information on IHS Markit: https://ihsmarkit.com/company/index.html
For more information on Syva: www.syva.es/en
You may also be interested in
29 November, 2021
Having a good communication is a key role for animal health companies
On Thursday 25th, the annual conference of the Vet+I Foundation, the benchmark technology platform in animal health, an initiative that brings together all private companies and institutions in the animal health sector to work on projects for the development of emerging technologies, was held in Madrid. Numerous company executives and personalities from the sector were invited, including our General...
7 October, 2021
Vaccination for control and prevention of anthrax outbreaks
Anthrax is a serious disease caused by highly virulent spores of the bacterium Bacillus anthracis. If effective measures are not taken, anthrax can decimate herds of many farm animals, including cattle and horses.
2 September, 2021
A step forward in the fight against swine erysipelas
For more than 60 years, Syva has been working with veterinarians and pig farmers in the fight against swine erysipelas. Epidemiological studies show that 30-50% of apparently healthy pigs carry Erysipelothrix rhusiopathiae1 bacteria. When uncontrolled, swine erysipelas can affect all stages of pig production, both in white and Iberian pigs, and cause a significant economic impact. The most frequent losses are...